- Home
- WIA vs NTHI Comparison
WIA vs NTHI Comparison
Compare WIA & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- NTHI
- Stock Information
- Founded
- WIA 2003
- NTHI 2008
- Country
- WIA United States
- NTHI United States
- Employees
- WIA N/A
- NTHI N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- NTHI Health Care
- Exchange
- WIA Nasdaq
- NTHI Nasdaq
- Market Cap
- WIA 197.8M
- NTHI 211.9M
- IPO Year
- WIA N/A
- NTHI N/A
- Fundamental
- Price
- WIA $8.35
- NTHI $9.67
- Analyst Decision
- WIA
- NTHI
- Analyst Count
- WIA 0
- NTHI 0
- Target Price
- WIA N/A
- NTHI N/A
- AVG Volume (30 Days)
- WIA 39.2K
- NTHI 35.5K
- Earning Date
- WIA 01-01-0001
- NTHI 11-19-2025
- Dividend Yield
- WIA 12.29%
- NTHI N/A
- EPS Growth
- WIA N/A
- NTHI N/A
- EPS
- WIA N/A
- NTHI N/A
- Revenue
- WIA N/A
- NTHI $59,990.00
- Revenue This Year
- WIA N/A
- NTHI N/A
- Revenue Next Year
- WIA N/A
- NTHI N/A
- P/E Ratio
- WIA N/A
- NTHI N/A
- Revenue Growth
- WIA N/A
- NTHI N/A
- 52 Week Low
- WIA $7.56
- NTHI $3.20
- 52 Week High
- WIA $8.91
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- WIA 43.48
- NTHI N/A
- Support Level
- WIA $8.37
- NTHI N/A
- Resistance Level
- WIA $8.54
- NTHI N/A
- Average True Range (ATR)
- WIA 0.06
- NTHI 0.00
- MACD
- WIA -0.01
- NTHI 0.00
- Stochastic Oscillator
- WIA 17.61
- NTHI 0.00
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).